Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of arsenic trioxide with or without
ascorbic acid in treating patients with myelofibrosis. Drugs used in chemotherapy, such as
arsenic trioxide, work in different ways to stop the growth of cancer cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving
arsenic acid together with ascorbic acid may kill more cancer cells.